Lipid Disorder Treatment Market, By Indication (Hypercholesterolemia (Primary Hypercholesterolemia, Familial Hypercholesterolemia), Hypertriglyceridemia, Mixed Dyslipidemia (Elevated LDL-C and Triglycerides, Low HDL-C with Elevated LDL-C), Atherosclerotic Cardiovascular Disease (ASCVD), Familial Lipoprotein Lipase Deficiency, and Others (Hereditary Transthyretin-Mediated Amyloidosis)), By Drug Class (Statins (Atorvastatin, Rosuvastatin, Simvastatin, Others (Pravastatin, etc.)), PCSK9 Inhibitors (Alirocumab, Evolocumab, Others (Pravastatin, etc.)), Bile Acid Sequestrants (Colesevelam, Colestipol, Others (Cholestyramine, etc.)), Cholesterol Absorption Inhibitors,(Ezetimibe, Bempedoic Acid), Fibrates, (Fenofibrate, Gemfibrozil), Niacin (Vitamin B3), (Nicotinic Acid), Omega-3 Fatty Acids, (Icosapent ethyl (Vascepa), Omega-3-acid ethyl esters (Lovaza)), Combination Therapies, (Ezetimibe/Statin Combinations), and Other Late Phase Drugs By Type: Generic and Brand), By Route of Administration (Oral and Parenteral), By Age Group (Adults, Pediatric, and Geriatric), By Gender (Male and Female), By Distribution Channel (Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)